

Salvatore Geraci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2857081/publications.pdf>

Version: 2024-02-01

29
papers

1,497
citations

623734

14
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

1764
citing authors

#	ARTICLE	IF	CITATIONS
1	Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 278-280.	1.5	1
2	ImpaCt of an Optimal Implantation Strategy on Absorb Long-Term Outcomes: The CIAO Registry. <i>Cardiovascular Revascularization Medicine</i> , 2021, 30, 1-8.	0.8	1
3	Prognostic Value of QFR Measured Immediately After Successful Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2079-2088.	2.9	103
4	Sirolimus-Eluting Magnesium Resorbable Scaffold Implantation in Patients with Acute Myocardial Infarction. <i>Cardiology</i> , 2019, 142, 93-96.	1.4	11
5	The impact of the use of bioresorbable vascular scaffolds and drug-coated balloons in coronary bifurcation lesions. <i>Egyptian Heart Journal</i> , 2019, 71, 31.	1.2	2
6	Coronary Artery Fistulae: Anatomy, Diagnosis and Management Strategies. <i>Heart Lung and Circulation</i> , 2018, 27, 940-951.	0.4	112
7	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicenter GHOST-EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 444-453.	1.7	8
8	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 560-568.	2.9	16
9	Bioresorbable Vascular Scaffolds as a Treatment Option for Left Main Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 743-745.	2.9	1
10	A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1855-1864.	2.9	22
11	Reply. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1275-1276.	2.9	0
12	Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 812-818.	1.7	15
13	Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 47-56.	1.7	28
14	A lesson from intravascular imaging: insights for recognizing a spontaneous coronary artery dissection. <i>Journal of Thoracic Disease</i> , 2017, 9, 5363-5367.	1.4	8
15	Should we reconsider dual antiplatelet therapy duration following bioresorbable scaffold angioplasty?. <i>Journal of Thoracic Disease</i> , 2017, 9, 417-418.	1.4	4
16	Effectiveness and safety of the ABSORB bioresorbable vascular scaffold for the treatment of coronary artery disease: systematic review and meta-analysis of randomized clinical trials. <i>Journal of Thoracic Disease</i> , 2017, 9, S887-S897.	1.4	8
17	Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry. <i>EuroIntervention</i> , 2017, 13, e1104-e1111.	3.2	9
18	Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. <i>EuroIntervention</i> , 2017, 12, 2110-2117.	3.2	114

#	ARTICLE	IF	CITATIONS
19	One-year clinical results of the Italian diffuse/multivessel disease ABSORB prospective registry (IT-DISAPPEARS). EuroIntervention, 2017, 13, 424-431.	3.2	15
20	Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. EuroIntervention, 2017, 13, 432-439.	3.2	98
21	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 440-449.	2.9	23
22	Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the "no more metallic cages" multicentre pilot experience. EuroIntervention, 2016, 11, e1589-e1595.	3.2	13
23	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. EuroIntervention, 2016, 12, e550-e556.	3.2	32
24	Effect of Inorganic Nitrate on Exercise Capacity in Heart Failure With Preserved Ejection Fraction. Circulation, 2015, 131, 371-380.	1.6	251
25	Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention, 2015, 10, 1144-1153.	3.2	411
26	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention, 2015, 11, 45-52.	3.2	131
27	Effective Arterial Elastance Is Insensitive to Pulsatile Arterial Load. Hypertension, 2014, 64, 1022-1031.	2.7	48
28	Acute coronary syndrome due to early multiple and complete fractures in sirolimus-eluting stent: A case report and brief literature review. Catheterization and Cardiovascular Interventions, 2013, 81, 52-56.	1.7	5
29	How should I treat a massive thrombus embolisation in the left coronary artery during chronic total occlusion revascularisation?. EuroIntervention, 2012, 8, 866-875.	3.2	0